---
schema_version: "secwatch.filing_event.v1"
accession: "0001468492-25-000011"
form_type: "8-K"
ticker: "HSCS"
cik: "0001468492"
company_name: "HeartSciences Inc."
filed_at: "2025-09-11T23:59:59+00:00"
generated_at: "2026-05-17T06:52:00.504446+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# HeartSciences reports Q1 FY2026 with $2.8M cash; launches MyoVista Insights platform

## Summary
- No meaningful revenue for Q1 FY2026; cash and equivalents $2.8M, shareholders' equity $3.1M as of July 31, 2025.
- Post-quarter raised $0.8M via Reg A+ and exchanged $0.7M debt into equity, strengthening balance sheet.
- FDA granted Breakthrough Device designation for aortic stenosis ECG algorithm; now holds 44 granted patents.
- Launched MyoVista Insights cloud-native platform; phased rollout began May 2025.
- Separate FDA submissions planned for MyoVista wavECG device and algorithm, targeting clearances in 2026.

## SEC filing metadata
- accession: 0001468492-25-000011
- form_type: 8-K
- ticker: HSCS
- cik: 0001468492
- company_name: HeartSciences Inc.
- filed_at: 2025-09-11T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1468492/000146849225000011/0001468492-25-000011-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1468492/000146849225000011/hscs-20250911.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001468492-25-000011
- JSON: https://secwatch.observer/filing/0001468492-25-000011.json
- Plain text: https://secwatch.observer/filing/0001468492-25-000011.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.